Health Economics and Outcomes Research

Researchers compared the overall survival, cancer-specific survival, and associated costs of trimodal therapy versus radical cystectomy for patients with localized muscle-invasive bladder cancer.
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost effective.
In a recent study, researchers evaluated the role of autologous stem cell transplantation in patients with multiple myeloma in the context of novel agents.
Immunotherapy treatment past progression for patients with advanced lung cancer may account for 29% of total treatment costs, without clear value for most patients, according to a presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium.
A comparative effectiveness study examined the costs associated with short-course radiation therapy versus long-course chemoradiation for locally advanced rectal adenocarcinoma.
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.
A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective.
Lung cancer screening based on individual risk may save more lives than current USPSTF estimations but is less efficient in terms of cost and quality of life-years gained.
A 21-gene assay poses an overall incremental cost increase to the health care system in the short-term, despite lower rates of chemotherapy use.
Although the ASCO Value Framework can help quantify the health value and benefit of various cancer therapies, it has essential limitations for its use in the treatment of chronic lymphocytic leukemia.